---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-022588"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:08:48.150902+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Novavax Chair James Young retires; Margaret McGlynn named successor; John Shiver joins board

## Summary
- James Young, PhD resigned as Board Chair effective March 10, 2025, after 15 years on the board.
- Margaret McGlynn, former Merck Vaccines president, appointed as Chair of the Board.
- John Shiver, PhD appointed as independent director; has 30+ years vaccine/RNA experience.
- Shiver receives initial equity grant of 35,770 options and 23,480 RSUs.
- No disagreement cited; changes part of planned board succession.

## SEC filing metadata
- accession: 0001104659-25-022588
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465925022588/0001104659-25-022588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465925022588/tm258808d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-022588
- JSON: https://secwatch.observer/filing/0001104659-25-022588.json
- Plain text: https://secwatch.observer/filing/0001104659-25-022588.txt

## Key facts
- Executive change
  James F. Young resigned as Chairperson of the Board at NOVAVAX INC.
  - Action: resigned
  - Role: Chairperson of the Board
  source text: On March 10, 2025, James F. Young, Ph.D. resigned from the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”), effective as of March 10, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465925022588/0001104659-25-022588-index.htm
- Executive change
  John W. Shiver was appointed as Director at NOVAVAX INC.
  - Action: appointed
  - Role: Director
  source text: On March 10, 2025, the Board appointed John W. Shiver, Ph.D. to the Company’s Board, effective on such date, to fill the vacancy created by Dr. Young’s resignation and to serve as a Class III director for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465925022588/0001104659-25-022588-index.htm
- Executive change
  Margaret G. McGlynn was appointed as Chairperson of the Board at NOVAVAX INC.
  - Action: appointed
  - Role: Chairperson of the Board
  source text: Margaret G. McGlynn was appointed to serve as the Chairperson of the Board to succeed Dr. Young.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465925022588/0001104659-25-022588-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.